This article is more than 5 years old. Information may no longer be current.
Healio.com to provide live coverage of The Liver Meeting 2015
Click Here to Manage Email Alerts
Healio.com/Hepatology will offer live coverage from The Liver Meeting beginning Saturday.
The conference, held November 13 to November 17 in San Francisco, California, will feature experts speaking on critical topics within hepatology, such as hepatitis C virus infection and nonalcoholic fatty liver disease.
According to the AASLD website, more than 9,500 hepatologists and health professionals from around the world will gather in San Francisco to exchange ideas on the latest liver disease research, discuss treatment outcomes and interact with colleagues at the annual must-attend event in the field of hepatology.
“The Liver Meeting is probably the most exciting meeting for hepatologists and anyone interested in treating patients with liver disease, studying liver diseases or anything having to do with liver and medicine,” Gyongyi Szabo, MD, PhD, FAASLD, associate dean for clinical and translational research at the University of Massachusetts Medical School, and AASLD president, said in a video interview on the AASLD website. “This will be a very exciting meeting.”
Gyongyi Szabo
According to Szabo, AASLD is launching a new format for learning at The Liver Meeting. These include new opportunities in learning for various special interest groups and a new format for people interested in basic and translational research.
“I think the buzz that happens at The Liver Meeting is that you get the networking, science and state-of-the-art clinical care updates and I think most people should just not miss The Liver Meeting,” Szabo said.
HCV Next Editorial Board members will also be in attendance, including: Jordan J. Feld, MD, who will be presenting a late breaking abstract of phase 3 results from the ASTRAL-1 trial, and Ira M. Jacobson, MD, who will be presenting a late breaking abstract of results from a clinical trial investigating the efficacy of Merck’s elbasvir and grazoprevir for the treatment of HCV genotype 1a infection.
Visit Healio.com/Hepatology to read the latest news from the meeting, and follow our live updates on Twitter at @HealioHep.
Disclosures: Please see the AASLD website for a full list of Szabo’s relevant financial disclosures.